Oncolytics Biotech's pelareorep boosts HPV-specific immune responses in anal cancer study
ONCY•Oncolytics Biotech presented data from an ongoing Phase 1/2 anal cancer trial, where pelareorep combined with a checkpoint inhibitor increased HPV-specific immune responses associated with tumor shrinkage. The company estimates the HPV-associated cancer market at $3 billion to $5 billion.
1. Trial findings
Oncolytics Biotech presented new data from an ongoing Phase 1/2 trial of pelareorep combined with a checkpoint inhibitor in previously treated patients with unresectable squamous cell anal cancer. Treatment increased HPV-specific immune responses associated with tumor shrinkage, while efficacy signals suggested better responses than the currently approved therapy.
2. Market opportunity
Management is seeking strategic collaborations targeting HPV-associated cancers, a market it estimates at $3 billion to $5 billion based on internal estimates.
